Know Cancer

forgot password

A Phase II Trial of Carboplatin Plus Paclitaxel in the Treatment of Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 2
18 Years
Not Enrolling
Head and Neck Cancer

Thank you

Trial Information

A Phase II Trial of Carboplatin Plus Paclitaxel in the Treatment of Locally Recurrent or Metastatic Nasopharyngeal Carcinoma

OBJECTIVES: I. Estimate the response and toxicity of carboplatin in combination with
paclitaxel in patients with locally recurrent or metastatic nasopharyngeal carcinoma.

OUTLINE: Patients receive paclitaxel IV over 3 hours followed by carboplatin IV over 30
minutes. This cycle is repeated every 3 weeks. Patients may receive 6-8 cycles of therapy in
the absence of toxicity and disease progression. Patients are followed every 3 months for
the first 2 years, every 6 months for the next 3 years, and yearly thereafter.

PROJECTED ACCRUAL: 30 eligible patients will be accrued in approximately 18 months.

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed locally recurrent or metastatic
nasopharyngeal carcinoma that is not curable with resection or radiation therapy
Bidimensionally measurable disease

PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-1 Life expectancy:
Not specified Hematopoietic: Absolute neutrophil count greater than 1500/mm3 Platelet
count greater than 100,000/mm3 Hepatic: Bilirubin less than 1.5 mg/dL Renal: Creatinine
less than 3.0 mg/dL Other: No active infections Serum calcium within institutional normal
range No history of hypercalcemia Prior malignancy other than nasopharyngeal carcinoma
allowed No concurrent malignancy Not pregnant or lactating Fertile patients must use
effective contraception

PRIOR CONCURRENT THERAPY: Biologic therapy: Prior biologic therapy allowed Chemotherapy:
No prior chemotherapy for metastatic or recurrent disease Prior induction or adjuvant
chemotherapy concurrent with radiation therapy allowed No prior treatment with paclitaxel
Endocrine therapy: Not specified Radiotherapy: See Chemotherapy Surgery: Not specified

Type of Study:


Study Design:

Primary Purpose: Treatment

Principal Investigator

Barbara A. Murphy, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Vanderbilt-Ingram Cancer Center


United States: Federal Government

Study ID:




Start Date:

April 1998

Completion Date:

Related Keywords:

  • Head and Neck Cancer
  • stage IV nasopharyngeal cancer
  • recurrent nasopharyngeal cancer
  • Head and Neck Neoplasms
  • Nasopharyngeal Neoplasms



Stanford University Medical Center Stanford, California  94305-5408
H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida  33612
Emory University Hospital - Atlanta Atlanta, Georgia  30322
University of Rochester Cancer Center Rochester, New York  14642
Ireland Cancer Center Cleveland, Ohio  44106-5065
Fox Chase Cancer Center Philadelphia, Pennsylvania  19111
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, Illinois  60611
Veterans Affairs Medical Center - Atlanta (Decatur) Decatur, Georgia  30033
CCOP - Illinois Oncology Research Association Peoria, Illinois  61602
CCOP - Kalamazoo Kalamazoo, Michigan  49007-3731
CCOP - Metro-Minnesota Saint Louis Park, Minnesota  55416
Veterans Affairs Medical Center - East Orange East Orange, New Jersey  07018-1095
CCOP - Northern New Jersey Hackensack, New Jersey  07601
Vanderbilt Cancer Center Nashville, Tennessee  37232-6838
CCOP - Cedar Rapids Oncology Project Cedar Rapids, Iowa  52403-1206
Veterans Affairs Medical Center - Chicago (Lakeside) Chicago, Illinois  60611
Veterans Affairs Medical Center - Palo Alto Palo Alto, California  94304